Cleerly Raises $43M in Series B Funding

Cleerly, a NYC-based company creating a new standard of care for heart disease, launched with $43m in Series B funding.

The round, which brings Cleerly’s total funding to $54m, was led by Vensana Capital with participation from LRVHealth, New Leaf Venture Partners, DigiTx Partners, the American College of Cardiology, Cigna Ventures, and existing investors. As part of the financing, Justin Klein of Vensana Capital, Tripp Peake of LRVHealth and Vijay Lathi of New Leaf Venture Partners will join Cleerly’s Board of Directors.

The company intends to use the funds to scale its commercial reach, expand operational capabilities and strategic partnerships, and continue to grow its focus on research and development.

Founded in 2017 by James K. Min, MD FACC, and founder and CEO, Cleerly has launched its digital care pathway solution for heart attack prevention powered by proprietary artificial intelligence (AI) and machine learning algorithms.

Its digital care pathway leverages non-invasive coronary computed tomography (CT) angiography to perform comprehensive coronary artery phenotyping through AI-enabled and FDA-cleared solutions. This technology is based on millions of annotated lab images used to build more than two dozen proprietary algorithms capable of quantifying and characterizing the presence, extent, severity and type of coronary artery disease and other cardiovascular disorders.

FinSMEs

21/06/2021